Occudo Quantitative Strategies LP Invests $379,000 in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Occudo Quantitative Strategies LP acquired a new position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,539 shares of the biopharmaceutical company’s stock, valued at approximately $379,000.

Other large investors also recently made changes to their positions in the company. Accredited Wealth Management LLC acquired a new stake in shares of Intra-Cellular Therapies in the fourth quarter worth $28,000. Venturi Wealth Management LLC acquired a new stake in Intra-Cellular Therapies during the 4th quarter valued at $96,000. Wilmington Savings Fund Society FSB grew its holdings in Intra-Cellular Therapies by 55.7% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 2,069 shares of the biopharmaceutical company’s stock valued at $173,000 after purchasing an additional 740 shares in the last quarter. Covestor Ltd grew its holdings in Intra-Cellular Therapies by 15.9% during the 4th quarter. Covestor Ltd now owns 2,099 shares of the biopharmaceutical company’s stock valued at $175,000 after purchasing an additional 288 shares in the last quarter. Finally, Barlow Wealth Partners Inc. acquired a new position in Intra-Cellular Therapies during the 4th quarter worth $184,000. Institutional investors and hedge funds own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of Intra-Cellular Therapies stock opened at $131.87 on Friday. Intra-Cellular Therapies, Inc. has a 52-week low of $64.09 and a 52-week high of $131.98. The company’s fifty day moving average price is $131.78 and its two-hundred day moving average price is $113.44. The firm has a market capitalization of $14.05 billion, a PE ratio of -151.57 and a beta of 0.69.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its quarterly earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. The company had revenue of $199.22 million for the quarter, compared to analyst estimates of $205.08 million. Analysts predict that Intra-Cellular Therapies, Inc. will post -0.64 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on ITCI shares. Canaccord Genuity Group downgraded shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and raised their price target for the stock from $119.00 to $132.00 in a research report on Friday, January 31st. Mizuho cut shares of Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $140.00 to $132.00 in a research note on Monday, February 24th. Needham & Company LLC reissued a “hold” rating on shares of Intra-Cellular Therapies in a research report on Friday, February 21st. Cantor Fitzgerald reiterated a “neutral” rating and issued a $132.00 target price on shares of Intra-Cellular Therapies in a research note on Wednesday, April 2nd. Finally, StockNews.com initiated coverage on shares of Intra-Cellular Therapies in a research note on Thursday. They issued a “hold” rating for the company. Eleven investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Intra-Cellular Therapies has a consensus rating of “Hold” and an average price target of $109.70.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.